VHL Antilichaam

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.

7428

P40337

Human, Mouse, Rat

A synthetic peptide corresponding to a sequence within amino acids 1-100 of human VHL (NP_937799.1) .

Unconjugated

Primary Antibodies

Apoptosis, Cancer, Cell Cycle, Immunology

Affinity purification

Batch dependent

PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

None

Blue Ice

Store at -20˚ C. Avoid freeze / thaw cycles.

Observed: 24kDa

IgG

VHL

Von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase

Homo sapiens

VHL, von Hippel-Lindau tumor suppressor, HRCA1, RCA1, VHL1, elongin binding protein, von Hippel-Lindau syndrome, pVHL

WB, IHC

Liquid